The Daily Brief

October 28, 2026

Federal courts are reasserting jurisdiction over cannabis disputes that state systems have dismissed, even as the market itself generates record revenues and political momentum continues building toward expanded legalization across the country.

A federal appeals court revived a lawsuit this week against the City of Blue Island, Illinois, after the municipality denied a bakery license to Mary Jane Sweet Spot LLC and owner Ashley McCoy following events featuring "infused" treats. The U.S. Court of Appeals for the Seventh Circuit reversed a lower court dismissal, ruling that federal constitutional claims—including due process and equal protection violations—deserve consideration in federal court, even though the case involves a state licensing decision. The dispute traces back to 2021, when McCoy's application initially appeared headed for approval until city officials learned of themed events the business had hosted before receiving authorization, including an October costume party advertised with infused treats, alcohol, and hookah smoking. Context This decision signals that cannabis-adjacent legal disputes are increasingly reaching federal dockets, creating new constitutional battlegrounds around local regulatory authority.

Meanwhile, economic and legislative developments are reshaping the cannabis landscape at state and tribal levels. Money New York crossed $4.1 billion in legal marijuana sales since the market launched in late 2022, with $1.41 billion in sales already logged in 2026 alone—numbers Governor Kathy Hochul cited this week as evidence that legalization is delivering on promises of equity and community reinvestment. In a different revenue context, Native American tribes stand to capture more than $2 billion annually by entering regulated cannabis markets, according to analysis from HedgeRow, which projects tribal nations moving "deliberately and early" could generate $300 million to $600 million within five years by serving unmet demand in prohibition states and medical-only jurisdictions where consumers currently turn to unregulated products.

Legislative battles over tax structure and market design are intensifying in established cannabis states. Michigan state representative Jay DeBoyer, running for lieutenant governor, plans to introduce legislation suspending the state's 24 percent wholesale marijuana tax for twelve months to reassess its impact on industry viability and consumer prices. Nevada is similarly reconsidering its excise tax structure as cannabis tax revenue has diminished in the mature market. These moves reflect a pattern: as legalized markets mature, policymakers are trading aggressive early taxation for market stability and tax base preservation.

Federal hemp policy remains the most volatile arena. Law enforcement agencies have already raided and charged dozens of hemp operators across the country more than six weeks before a new federal ban on intoxicating hemp-derived THC products takes effect, signaling aggressive enforcement ahead of the deadline. Representative Morgan Griffith (R-Va.) is preparing legislation to regulate intoxicating hemp products and avert an outright ban by attaching it to a post-election reconciliation bill—a strategy that acknowledges the political difficulty of killing an industry without offering an alternative framework. Notable A federal appeals court also ordered reconsideration of a Georgia man's firearms conviction for possessing guns while using marijuana, citing the U.S. Supreme Court's June ruling that prosecutors cannot automatically strip Second Amendment rights based solely on regular cannabis use. The decision underscores how Supreme Court precedent is now forcing lower courts to reconsider convictions and guilty pleas in cases involving both marijuana and other substances.

Looking ahead to 2027, ten states remain positioned to legalize recreational marijuana legislatively or via ballot initiative. Pennsylvania leads candidates for becoming the 25th state to legalize, particularly if the November 3 election produces Democratic gains in the state Senate; Massachusetts voters are simultaneously deciding whether to repeal the state's existing legalization via Question 8—a vote NORML calls an uphill battle for prohibitionists, noting no state has ever reversed a legalization law despite increasing reliance on sensational rhetoric. Hawaii, New Hampshire, Wisconsin, and Florida all have active legalization measures or ballot processes advancing. Context Twenty-four states and Washington, D.C. now permit adult-use cannabis, a seismic shift from the two states that had legalized a decade ago, yet federal prohibition persists while states and tribes race to capture expanding market opportunity.

October 28, 2026

New York's legal cannabis market has surpassed $4.1 billion in cumulative retail sales, with Governor Kathy Hochul highlighting the achievement as proof that the state's legalization promise is delivering real economic opportunity. The milestone comes less than four years after recreational sales began in December 2022, and New York now operates 744 licensed adult-use dispensaries across the state with 1,039 retail licenses issued overall. Money The market generated $1.41 billion in sales through the third quarter of 2026 alone, pushing New York into third place nationally for adult-use marijuana retail sales. The state has also prioritized equity, with 56% of adult-use licenses awarded to social and economic equity applicants, addressing communities most impacted by decades of prohibition.

Across the country, research is revealing how local policy decisions shape market access and consumer behavior in ways that national legalization statistics often obscure. A Yale University and University of Nevada, Reno study published in the International Journal of Drug Policy found that local municipal bans on marijuana dispensaries significantly increase travel times to legal retailers—42% longer in Washington state and 20% longer in California. The analysis examined 864,616 product-level sales observations and found that even as the legal market matures, geography still determines who can easily access licensed products. Context In New Jersey, 55% of residents live in jurisdictions that prohibit recreational marijuana retailers, while only 1.5% of New Yorkers face similar local restrictions—a stark difference in how legalization actually reaches people on the ground.

Price sensitivity is reshaping cannabis markets nationwide as supply stabilizes and competition drives down costs. A federally funded study from UC San Diego found that a 1% drop in marijuana prices correlates with a 2.29% increase in quantity purchased, meaning consumers respond substantially to even modest price changes. Median flower prices fell from $8.23 per gram in 2020 to $6.12 in 2023—a 26% decline—with Nevada seeing particularly dramatic compression: retail flower prices dropped 50% from $9.02 per gram in 2019 to $4.46 in 2025. Notable These price trends reflect a maturing market where increased production capacity, efficiency gains, and legitimate competition are lowering costs for consumers, though they're also pressuring state tax revenue.

That pressure is forcing states to rethink tax structures. Nevada lawmakers are studying whether to eliminate the state's 15% wholesale excise tax and increase retail excise taxes by 2-5% instead, acknowledging that the current formula has failed to keep pace with falling prices and is now generating 40% less revenue than its 2021 peak. Cultivators have argued that the state's "fair market value" calculation for wholesale taxation lags behind actual price declines, resulting in effective overtaxation. The subcommittee reviewing the proposal emphasized it was only studying impacts, not recommending changes, but the underlying economic reality is clear: as mature markets stabilize, tax policy designed for rapid growth no longer fits the landscape.

South Africa's KwaZulu-Natal province is attempting to expand hemp cultivation through a new seed production program aimed at bringing more farmers into commercial growing, signaling international interest in establishing legitimate cannabis supply chains outside traditionally dominant markets. Meanwhile, enforcement against illegal operators continues: New York alone closed or padlocked 738 unlicensed marijuana storefronts and seized approximately $276.9 million in illicit product value since enforcement began, with 2026 operations alone accounting for 191 storefront closures and $125 million in seized inventory. The gap between legal and illegal markets remains a critical policy metric, particularly as price compression in licensed retail affects both consumer behavior and the viability of enforcement resources dedicated to protecting the legitimate industry.

October 28, 2026

Federal hemp restrictions set to take effect December 11 are forcing a showdown in Congress as businesses liquidate inventory and lawmakers debate whether to regulate or ban intoxicating hemp products entirely. Illinois retailers including Binny's Beverage Depot and UFS Outlet Center have begun clearing THC beverage stock ahead of the looming deadline, with Binny's posting a "COUNTDOWN to the THC BAN" header on its website and encouraging customers to purchase before supplies vanish. Money The hemp THC beverage market alone is projected to reach $5.6 billion by 2035, but that projection now hinges on Congressional action in the next six weeks. Under legislation passed in 2025, the federal definition of hemp narrows dramatically to exclude finished products containing more than 0.4 milligrams of total THC per container—a threshold that would eliminate most current hemp drinks and edibles sold outside licensed cannabis dispensaries.

The push to regulate rather than ban has bipartisan backing. Representative Morgan Griffith (R-VA) told Roll Call on Monday that provisions from his Hemp Enforcement, Modernization, and Protection (HEMP) Act could be combined with a beverage-focused tax measure and included in a budget reconciliation bill during the lame-duck session, allowing passage with a simple majority vote and circumventing the filibuster. Congressional Cannabis Caucus Co-Chair Dina Titus (D-NV) emphasized in an exclusive statement that marijuana and hemp-derived substances should be held to identical regulatory standards when they produce similar intoxicating effects, calling for consistent federal rules that protect consumers regardless of product classification. Context The December 11 deadline provides Congress approximately 45 days to act, though lawmakers have already extended the original November 12 restriction once to allow time for negotiation.

Meanwhile, states are taking divergent approaches to the impending federal changes. Rhode Island hemp businesses received permission to quarantine intoxicating inventory rather than destroy it, keeping options open if federal regulations shift. This measured approach stands in contrast to stricter state interpretations, with Peoria health officials having previously flagged concerns about inconsistent testing, product labeling, and safe service in bars and restaurants—issues that arise precisely because hemp-derived THC products occupy a regulatory gray area.

Notable On the research front, a peer-reviewed analysis published October 27 in Joint Bone Spine examined 43 clinical studies and found that cannabinoid-based treatments significantly improve pain and sleep quality in patients with rheumatic diseases, with the strongest evidence supporting their use for fibromyalgia. The French research team from Cochin Hospital and Université Paris Cité noted that cannabinoids were generally well tolerated across studies, though evidence remains inconsistent and additional large-scale trials are needed. Simultaneously, 29 clinical trials across U.S. universities and hospitals are actively recruiting participants to study cannabinoids for chronic pain, cancer-related symptoms, epilepsy, autism, and sleep disorders, indicating sustained federal research interest despite prohibition debates at the policy level.

A federally funded study published in *Drugs: Education, Prevention and Policy* revealed that cannabis consumers trust dispensary staff more than healthcare providers or government officials for cannabis information—dispensary workers scored 3.7 on a 1-5 trust scale compared to 3.4 for healthcare providers and 2.9 for state and federal officials. The research from UC, Johns Hopkins, and partner institutions found trust levels shift based on use context: when considering medical applications, 55 percent of respondents trusted healthcare providers most, but for recreational use, 47 percent favored dispensary staff. The gap underscores what researchers called a "need for integration of cannabis core competencies into healthcare provider education," as scientific and medical information about cannabis continues to lag behind rapidly expanding consumer markets.

October 28, 2026

Recent brain imaging research is challenging longstanding assumptions about marijuana use and schizophrenia. A study published October 23 in Schizophrenia Research, conducted by researchers from Université Lyon 1, McGill University, and French medical institutions, examined 51 patients with schizophrenia to determine whether cannabis consumption altered brain connectivity patterns associated with formal thought disorder—a hallmark symptom involving difficulties organizing thoughts and maintaining coherent speech. Using functional magnetic resonance imaging, the team compared marijuana users with nonusers and analyzed whether the THC-to-CBD ratio correlated with brain activity or symptom severity. Notable The results showed no statistically significant differences in brain connectivity between the two groups, and the THC-to-CBD ratio was not significantly associated with thought disorder symptoms. Bayesian analyses produced moderate to strong evidence supporting the absence of the relationships researchers had investigated, directly contradicting earlier assumptions that higher-THC products might exacerbate thought disorder in people with schizophrenia.

The findings underscore a growing pattern in cannabis science: controlled studies often reveal a more nuanced picture than earlier observational research suggested. The researchers acknowledged that their work points to the need for larger studies examining marijuana composition, consumption levels, dose-response relationships, and different symptom categories to better understand how cannabinoid exposure may relate to brain function in this population. Context The absence of detected harm in a rigorous neuroimaging study doesn't prove cannabis is without risk, but it does suggest that the relationship between cannabis use and schizophrenia symptomatology is far more complicated than simplified public health messaging has traditionally portrayed.

Separately, a new epidemiological study examining older cannabis users found that approximately 1 in 9 may meet diagnostic criteria for cannabis use disorder, highlighting that while cannabis carries a lower overdose risk profile than alcohol or prescription opioids, dependency patterns warrant attention in specific populations. Money As cannabis markets mature, understanding these demographic patterns becomes critical for both public health policy and industry compliance frameworks, particularly as more states and jurisdictions expand adult-use and medical programs targeting aging populations seeking alternatives for pain management and anxiety.

Research on cannabis retail proximity and adolescent use patterns continues to challenge binary assumptions. A study examining whether increased cannabis stores near schools correlate with higher teen use found the relationship to be more complicated than a simple proximity-drives-consumption model, suggesting that retail density alone is not a reliable predictor of youth consumption rates. This stands in contrast to simpler narratives about cannabis retail expansion and youth access, indicating that policy interventions targeting teen use may benefit from evidence examining multiple social and regulatory factors rather than location-based restrictions alone.

Finally, cannabis companies face a competitive disadvantage in consumer understanding compared to established industries. Wine and tobacco producers have decades of consumer research, demographic targeting data, and brand loyalty frameworks that cannabis businesses are only beginning to develop. Money As the cannabis industry matures and consolidation accelerates, the ability to understand and serve specific consumer segments—from older adults managing chronic pain to veterans seeking PTSD relief—will increasingly separate market leaders from competitors operating without this foundational consumer intelligence.